Orbital and ocular adnexa lymphomas are rare neoplasms confined to the orbital region. The prognosis is generally favorable, with a high proportion of localized disease, indolent clinical course, prolonged disease-free intervals, and low lymphoma-related mortality rate. We report our experience on eleven patients with confirmed histological diagnosis of lymphoma stage IE-IIE, treated between 2010 and 2021 with radiotherapy alone or in association with chemotherapy or immunotherapy. Eight patients were treated with primary radiotherapy only, while three received previous systemic treatments. Six patients were treated with Proton beam therapy (PBT), and five with external beam radiotherapy (EBRT). The five-year local control rate was 98%; only one patient developed an out-of-field recurrence. We also conducted a comprehensive literature review using electronic databases (PubMed, EMBASE, and Cochrane Library). Articles were selected based on their pertinence to treatment of the ocular and adnexal lymphoma focusing on radiotherapy techniques (electron beam radiotherapy, photon beam radiotherapy, or proton beam radiotherapy), treatment total dose, fractionation schedule, early and late radio-induced toxicities, and patient’s clinical outcome. Radiotherapy is an effective treatment option for orbital lymphoma, especially as standard treatment in the early stage of orbital lymphoma, with excellent local control rate and low rates of toxicity.
眼眶及眼附属器淋巴瘤是一种局限于眼眶区域的罕见肿瘤。其预后通常良好，主要表现为疾病局限性强、临床病程进展缓慢、无病生存期长且淋巴瘤相关死亡率低。本文报告了2010年至2021年间收治的11例经组织学确诊为IE-IIE期淋巴瘤患者的诊疗经验，所有患者均接受单纯放疗或联合化疗/免疫治疗。其中8例患者仅接受根治性放疗，3例患者曾接受过全身性治疗。6例患者接受质子束治疗，5例接受外照射放疗。五年局部控制率达98%，仅1例出现野外复发。同时，我们通过电子数据库（PubMed、EMBASE和Cochrane图书馆）进行了系统的文献综述，筛选标准聚焦于眼及附属器淋巴瘤的放射治疗技术（电子束放疗、光子束放疗或质子束放疗）、总剂量、分割方案、早期与晚期放射性损伤以及患者临床结局的相关研究。放射治疗是眼眶淋巴瘤的有效治疗选择，尤其作为早期眼眶淋巴瘤的标准治疗方案，具有优异的局部控制率和较低的毒副作用发生率。
肿瘤(癌症)患者之家